Ladenburg raised the firm’s price target on TG Therapeutics (TGTX) to $45 from $43 and keeps a Buy rating on the shares. The company reported strong Briumvi revenue in Q3, the analyst tells investors in a research note. The firm now has increased confidence in Briumvi’s growth prospects.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics Boosts Revenue Outlook Amidst Growth
- B. Riley remains a buyer of TG Therapeutics on weakness following Q3 results
- TG Therapeutics price target raised to $55 from $49 at H.C. Wainwright
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
- TG Therapeutics reports Q3 EPS 2c, consensus 3c